Page 74 - 《中国药房》2024年12期
P. 74

芍药苷对妊娠期糖尿病大鼠糖代谢、炎症、氧化应激的改善作用

          及机制
                     Δ


                *
          刘桂英 ,牛 丽,常雪允,周秀云(阜阳市妇女儿童医院产科,安徽 阜阳 236000)
                                        #
          中图分类号  R965      文献标志码  A      文章编号  1001-0408(2024)12-1476-06
          DOI  10.6039/j.issn.1001-0408.2024.12.11

          摘   要  目的  基于核转录因子红系2相关因子2(Nrf2)/血红素加氧酶1(HO-1)/依赖还原型辅酶/醌氧化还原酶1(NQO1)信号通
          路探究芍药苷对妊娠期糖尿病(GDM)大鼠糖代谢、炎症、氧化应激的改善作用及潜在机制。方法  将以高脂高糖饲料喂养的雌性
          大鼠和以普通饲料喂养的雄性大鼠合笼,收集妊娠期大鼠,单次腹腔注射链脲佐菌素复制GDM模型。将造模成功的大鼠随机分
          为模型组,盐酸二甲双胍组(灌胃200 mg/kg盐酸二甲双胍),芍药苷低、高剂量组(分别灌胃45、90 mg/kg芍药苷),芍药苷+ML385
          组(灌胃90 mg/kg芍药苷并腹腔注射30 mg/kg Nrf2抑制剂ML385),每组12只;另取以普通饲料喂养的妊娠期大鼠12只,作为对
          照组。各组大鼠给予相应药物/生理盐水,每天1次,连续干预2周。检测其糖代谢指标[空腹血糖(FBG)、空腹胰岛素(FINS)、胰
          岛素抵抗指数(HOMA-IR)]、血清炎症因子[白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)]和肾组织氧化应激指标[超氧化物歧化
          酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)]水平,观察肾组织病理变化,并检测肾组织中Nrf2、HO-1、NQO1蛋白
          的表达情况。结果  与对照组相比,模型组大鼠肾组织病变明显,可见肾小球萎缩、肾小管上皮细胞水肿变性和大量炎症细胞浸
          润;FBG、FINS水平,HOMA-IR,血清IL-6、TNF-α水平,以及肾组织中MDA水平均显著升高(P<0.05);肾组织中SOD、GSH-Px水
          平和Nrf2、HO-1、NQO1蛋白的表达水平均显著降低(P<0.05)。与模型组相比,芍药苷低、高剂量组大鼠肾组织病变有所减轻,上
          述各定量指标均显著改善,且芍药苷高剂量组的改善效果更优(P<0.05);ML385可显著逆转芍药苷对上述指标的改善作用(P<
          0.05)。结论  芍药苷可改善GDM大鼠的糖代谢异常、炎症和肾组织氧化应激损伤,上述作用可能与激活Nrf2/HO-1/NOQ1信号通
          路有关。
          关键词  芍药苷;妊娠期糖尿病;炎症;氧化应激;Nrf2/HO-1/NQO-1信号通路

          Improvement  effect  and  mechanism  of  paeoniflorin  on  glucose  metabolism,  inflammation  and  oxidative
          stress in rats with gestational diabetes mellitus

          LIU Guiying,NIU Li,CHANG Xueyun,ZHOU Xiuyun(Dept.  of  Obstetrics,  Fuyang  Women  and  Children’s
          Hospital, Anhui Fuyang 236000, China)

          ABSTRACT    OBJECTIVE To explore the effect of paeoniflorin on glucose metabolism, inflammation and oxidative stress in rats
          with  gestational  diabetes  mellitus (GDM)  and  its  potential  mechanism  based  on  nuclear  factor-erythroid  2-related  factor  2 (Nrf2)/
          heme  oxygenase-1 (HO-1)/nicotinamide  adenine  dinucleotide  phosphate:quinone  oxidoreductase  1 (NQO1)  signaling  pathway.
          METHODS  The  female  rats  fed  with  high  fat  and  high  sugar  diet  and  the  male  rats  fed  with  an  ordinary  diet  were  caged,  the
          successfully  conceived  rats  were  collected,  and  streptozotocin  was  injected  intraperitoneally  once  to  induce  the  GDM  model.  The
          successfully  modeled  rats  were  randomly  divided  into  the  model  group,  metformin  hydrochloride  group (200  mg/kg  metformin  by
          gavage),  paeoniflorin  low-,  high-dose  groups (45,  90  mg/kg  paeoniflorin  by  gavage,  respectively),  paeoniflorin+ML385  group
         (90 mg/kg paeoniflorin by gavage and intraperitoneal injection of 30 mg/kg Nrf2 inhibitor ML385), with 12 rats in each group; in
          addition, another 12 conceived rats fed with an ordinary diet were selected as the control group. The rats in each drug group were
          given  the  corresponding  drug/normal  saline,  once  a  day,  for  2  consecutive  weeks.  Glucose  metabolism  indexes  [fasting  blood
          glucose (FBG), fasting insulin (FINS), insulin resistance index (HOMA-IR)], serum inflammatory factors [interleukin-6 (IL-6),
          tumor  necrosis  factor- α (TNF- α)]  and  renal  tissue  oxidative  stress  indexes  [superoxide  dismutase (SOD),  malondialdehyde
                                                             (MDA),  glutathione  peroxidase (GSH-Px)]  were  detected;
              Δ 基金项目 安徽省卫生健康委科研项目(No.AHWJ2022b118)
             *第一作者 副主任医师。研究方向:妊娠期糖尿病诊治。E-                     the  pathological  changes  of  renal  tissue  were  observed,  and
          mail:liuguiy637@163.com                             the  protein  expressions  of  Nrf2,  HO-1  and  NQO1  in  renal
              # 通信作者 副主任医师。研究方向:产科疾病诊治。E-mail:
                                                              tissue  were  detected.  RESULTS  Compared  with  the  control
          13643347816@163.com

          · 1476 ·    China Pharmacy  2024 Vol. 35  No. 12                            中国药房  2024年第35卷第12期
   69   70   71   72   73   74   75   76   77   78   79